Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel ROR gamma t inverse agonists.
Jiang, B., Duan, J.J., Stachura, S., Karmakar, A., Hemagiri, H., Raut, D.K., Gupta, A.K., Weigelt, C.A., Khan, J., Sack, J.S., Wu, D.R., Yarde, M., Shen, D.R., Galella, M.A., Mathur, A., Zhao, Q., Salter-Cid, L.M., Carter, P.H., Dhar, T.G.M.(2020) Bioorg Med Chem Lett 30: 127392-127392
- PubMed: 32738966 
- DOI: 10.1016/j.bmcl.2020.127392
- Primary Citation of Related Structures:  
6XFV - PubMed Abstract: 
A novel series of cis-3,4-diphenylpyrrolidines were designed as RORγt inverse agonists based on the binding conformation of previously reported bicyclic sulfonamide 1. Preliminary synthesis and structure-activity relationship (SAR) study established (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidine as the most effective scaffold ...